Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
Search by expertise, name or affiliation
High mobility group box 1 as a biomarker in critically ill patients
Eray Yagmur
, Lukas Buendgens
, Ulf Herbers
, Anne Beeretz
, Ralf Weiskirchen
,
Ger H. Koek
, Christian Trautwein
, Frank Tacke
*
, Alexander Koch
*
Corresponding author for this work
Interne Geneeskunde
MA Maag Darm Lever
NUTRIM - Liver and digestive health
Research output
:
Contribution to journal
›
Article
›
Academic
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'High mobility group box 1 as a biomarker in critically ill patients'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Nursing and Health Professions
Sepsis
100%
Intensive Care Unit
100%
Biological Marker
100%
Blood Level
66%
Critical Illness
66%
Disease Severity
33%
Inflammation
33%
Non Insulin Dependent Diabetes Mellitus
33%
Clinical Outcome
33%
Hemodialysis
33%
End Stage Renal Disease
33%
Medical Intensive Care Unit
33%
Experimental Sepsis
33%
INIS
patients
100%
mobility
100%
biological markers
100%
levels
40%
units
40%
plasma
30%
diseases
20%
concentration
20%
values
10%
mortality
10%
control
10%
comparative evaluations
10%
blood
10%
inflammation
10%
kidneys
10%
failures
10%
organs
10%
obesity
10%
Keyphrases
Critically Ill Patients
100%
High Mobility Group Box 1 (HMGB1)
100%
Sepsis
33%
Critical Illness
22%
Healthy Controls
11%
Immune System
11%
Type 2 Diabetes Mellitus (T2DM)
11%
Blood Samples
11%
Non-associated
11%
Plasma Parameters
11%
Systemic Inflammation
11%
Plasma Concentration
11%
Organ Failure
11%
Intensive Care Unit
11%
Disease Severity
11%
Prognostic Biomarker
11%
Intensive Care Unit Patients
11%
Diagnostic Biomarker
11%
Danger-associated Molecular Patterns
11%
End-stage Renal Disease Patients
11%
Obesity Type
11%
Surgical Intensive Care Unit
11%
Intensive Care Unit Admission
11%
Chronic Hemodialysis
11%
Experimental Sepsis
11%
Admissions Outcomes
11%
Mobility Group
11%
Clinical Outcomes
11%
Pathogenic Role
11%
Pharmacology, Toxicology and Pharmaceutical Science
Sepsis
100%
Biological Marker
100%
Critical Illness
66%
Inflammation
33%
Hemodialysis
33%
Disease Severity
33%
End Stage Renal Disease
33%
Experimental Sepsis
33%
Non Insulin Dependent Diabetes Mellitus
33%
Immunology and Microbiology
Blood Level
100%
Blood Plasma
50%
Systemic Inflammation
50%
Hemodialysis
50%
Prognostic Biomarker
50%
Immune System
50%
Biochemistry, Genetics and Molecular Biology
High-Mobility Group
100%
Blood Level
22%
Hemodialysis
11%
Blood Plasma
11%